Surgical Science Sweden AB (publ) (SUS) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Surgical Science Q4 Report 2025 presentation. During the Q&A session, participants can ask questions by pressing pound key 5 on their telephone keypad. During the Q&A, we kindly ask participants to limit yourselves to two questions at first. If you have additional questions, please queue up again by pressing pound key 5. Now, I will hand over to the speakers, CEO Tom Englund and CFO Anna Ahlberg. Please go ahead. Welcome to this earnings call for Surgical Science for the fourth quarter of 2025. My name is Tom Englund, CEO, and with me today, I have our CFO, Anna Ahlberg. We will first present the summary of quarter four and our results, and then we will have the Q&A session. We're pleased that like quarter three, quarter four was a clear step in the right direction for Surgical Science. We had sales of 269 million SEC and grew by 15%, adjusted for currency effects. And our license revenues, almost exclusively from robotics companies, were the highest ever reported at 92 million SEC, which was an increase of 21%. The adjusted EBIT amounted to 46 million, or 17%. On December 8th, Last year, we presented our new financial targets of annual sales growth of 10 to 15 percent with profitability of more than 15 percent. And it's gratifying to see that we're now delivering fourth quarter results in line with these targets. So if we move over to educational products, performance in educational products was mixed with growth of 4 percent. North and South America showed strong growth of 43% with a good distribution between the different countries. And we are seeing a clear recovery now in this region compared with previous quarters with a higher customer activity and bigger sales pipelines. And we're also cautiously optimistic about the future. Asia, on the other hand...